Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres.
J Glob Antimicrob Resist
; 37: 190-194, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38588973
ABSTRACT
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cilastatina
/
Imipenem
/
Compostos Azabicíclicos
/
Antibacterianos
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Glob Antimicrob Resist
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Holanda